Cowan Chad 4

4 · Century Therapeutics, Inc. · Filed Feb 4, 2026

AI-generated summary of this filing

Updated Feb 4, 2026

Century Therapeutics (IPSC) CSO Chad Cowan Receives RSU & Option Awards

What Happened

Chad Cowan, Chief Scientific Officer of Century Therapeutics (IPSC), received equity awards on Feb 2, 2026: 135,000 restricted stock units (RSUs) and 265,000 derivative awards (stock option-style). Both awards are reported with an acquisition price of $0 and therefore show $0 cash paid on the Form 4.

Key Details

Transaction date: Feb 2, 2026; Form 4 filed Feb 4, 2026 (covers the Feb 2 grants).
Award amounts: 135,000 RSUs; 265,000 derivative awards (stock options).
Reported acquisition price/value: $0 for both grants (common for issued awards).
Shares owned after transaction: not disclosed in this filing.
Footnotes of note:
- F1: The 135,000 RSUs each convert to one share and vest 25% on Feb 2, 2027, then the remaining 75% vests quarterly over the following three years; RSUs will be settled in shares upon vesting.
- F3: The 265,000 derivative award vests 25% on Feb 2, 2027, then the remaining 75% in 36 equal monthly installments (i.e., multi-year service-based vesting).
- F2: Notes certain shares are held by the Cowan Investment Nominee Trust and the reporting person disclaims beneficial ownership except for any pecuniary interest.

Context

These are grants/awards (not open-market purchases or sales). RSUs convert to shares only upon vesting; options (derivative awards) require future vesting and likely exercise before becoming stock—neither provides immediate sale proceeds.
Such grants are routine compensation for executives and should be read as long-term incentive awards rather than immediate market bets; the filing does not disclose any sale or cash exercise tied to these awards.

Form 4

Period: 2026-02-02

Chief Scientific Officer

Transactions

Award
Common Stock
[F1]
2026-02-02+135,000→ 1,178,476 total
Award
Stock Option (right to buy)
[F3]
2026-02-02+265,000→ 265,000 total
Exercise: $1.84Exp: 2036-02-02→ Common Stock (265,000 underlying)

Holdings

Footnotes (3)

[F1]Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.
[F2]Shares held by the Cowan Investment Nominee Trust. The Reporting Person disclaims beneficial ownership except to the extent of any pecuniary interest therein, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose.
[F3]The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

Signature

/s/ Douglas Carr, Attorney-in-Fact|2026-02-04

1 file